Coya Therapeutics Files 8-K: Officer/Director Changes & Compensation
Ticker: COYA · Form: 8-K · Filed: Apr 2, 2026 · CIK: 0001835022
| Field | Detail |
|---|---|
| Company | Coya Therapeutics, Inc. (COYA) |
| Form Type | 8-K |
| Filed Date | Apr 2, 2026 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: officer-departure, director-election, compensation
TL;DR
Coya Therapeutics filed an 8-K on 4/2/26 detailing leadership changes and compensation. Keep an eye on strategy shifts.
AI Summary
Coya Therapeutics, Inc. filed an 8-K on April 2, 2026, reporting changes in officers and directors, and compensatory arrangements. The filing includes exhibits detailing these changes and financial statements, with the period of report ending March 29, 2026.
Why It Matters
This filing signals potential shifts in Coya Therapeutics' leadership and executive compensation structure, which could impact the company's strategic direction and investor confidence.
Risk Assessment
Risk Level: medium — Changes in key personnel and compensation arrangements can introduce uncertainty regarding future company strategy and performance.
Key Players & Entities
- Coya Therapeutics, Inc. (company) — Filer of the 8-K report
- 0001835022 (company) — CIK number for Coya Therapeutics, Inc.
- 2026-04-02 (date) — Filing date of the 8-K
- 2026-03-29 (date) — Period of report end date
FAQ
What specific changes were made to Coya Therapeutics' officer or director positions?
The 8-K filing, specifically Item 5.02, details the departure of directors or certain officers, election of directors, and appointment of certain officers.
What type of compensatory arrangements are detailed in this filing?
Item 5.02 of the 8-K filing covers compensatory arrangements of certain officers.
When was this 8-K filing accepted by the SEC?
The filing was accepted on 2026-04-02 at 08:48:35.
What is the CIK number for Coya Therapeutics, Inc.?
The CIK number for Coya Therapeutics, Inc. is 0001835022.
Which exhibits are included with this 8-K filing?
The filing includes exhibits such as EX-10.1 and EX-99.1, along with XBRL data files.
Filing Stats: 1,097 words · 4 min read · ~4 pages · Grade level 10.8 · Accepted 2026-04-02 08:48:35
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share COYA The Nasdaq Stock Mar
Filing Documents
- d104763d8k.htm (8-K) — 30KB
- d104763dex101.htm (EX-10.1) — 45KB
- d104763dex991.htm (EX-99.1) — 14KB
- g104763g0401212644127.jpg (GRAPHIC) — 7KB
- 0001193125-26-139094.txt ( ) — 235KB
- coya-20260329.xsd (EX-101.SCH) — 3KB
- coya-20260329_lab.xml (EX-101.LAB) — 18KB
- coya-20260329_pre.xml (EX-101.PRE) — 11KB
- d104763d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. COYA THERAPEUTICS, INC. Date: April 2, 2026 By: /s/ Arun Swaminathan Ph.D. Arun Swaminathan Ph.D. Chief Executive Officer